ClinicalTrials.gg
Not yet recruitingNCT06463002AMPLEUpdated Jun 20, 2024

Ambulatory Blood Pressure Control and Cognition in Patients With Obstructive Sleep Apnea (AMPLE)

An observational study in Obstructive Sleep Apnea, sponsored by National University Hospital, Singapore. Not yet recruiting at 1 site in Singapore. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by National University Hospital, Singapore · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
150
Ages
22 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Sleep Apnea, Obstructive with a site in Singapore — 4 open to participants now, 4 under way, none of them phase 3. Sleep Apnea, Obstructive · Singapore.

Started
2024
with 2 others
Observational
7 of 18
2 open now
Registered
15th of 18
by date
Lead sponsor
3 of 18
National University Hospital, Singapore

Among the 18 studies in Sleep Apnea, Obstructive with a site in Singapore, this one is one of 3 that started in 2024, is one of 7 observational ones, and was the 15th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

4 of the 18 studies in Sleep Apnea, Obstructive with a site in Singapore are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 22 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Sleep Apnea, Obstructive with a site in Singapore, or all of them as a file.
02

Study summary

To compare the blood pressure control and cognitive responses of three groups of patients: those diagnosed with Obstructive Sleep Apnea (OSA) and treated with Continuous Positive Airway Pressure (CPAP) for at least six months, those diagnosed with OSA but not treated, and those without OSA.

Read the detailed description

This study is designed as an observational, cross-sectional investigation at the National University Hospital and Alexandra Hospital. The research aims to enroll 50 eligible patients in each of the three groups (OSA treated, OSA untreated, and non-OSA, totaling 150 participants). The recruited participants will undergo ambulatory blood pressure monitoring (ABPM) and the Montreal Cognitive Assessment (MoCA). ABPM is a widely used, noninvasive method to determine patients' blood pressure control. MoCA is a widely used screening tool designed to assess cognitive function and detect mild cognitive impairment or early signs of dementia. The MoCA evaluates various cognitive domains, including attention, memory, language, visuospatial abilities, executive functions, and orientation. It consists of a series of tasks and questions that assess different aspects of cognitive functioning, such as drawing specific shapes, recalling words or numbers, and performing simple calculations. A trained healthcare professional will administer the digital version of the MoCA, which usually takes less than 30 minutes to complete. The MoCA has been validated for use in diverse populations and has shown good sensitivity in detecting mild cognitive impairment. The maximum score on the MoCA is 30. Lower scores may indicate potential cognitive impairment.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Obstructive Sleep Apnea
  • Hypertension
  • Cognitive impairment
04

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals who fulfil the inclusion criteria but not the exclusion criteria will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Known OSA (AHI >/=15 events/ hour, based on sleep study) on CPAP treatment for at least six months (n=50)
  • Known OSA (AHI >/=15 events/ hour, based on sleep study) NOT on CPAP treatment (n=50)
  • Known non-OSA (AHI \<15 events/ hour, based on sleep study) (n=50)

Exclusion criteria

Exclusion Criteria:

  • Known-OSA on non-CPAP treatment (e.g., mandibular advancement device, surgery, or hypoglossal nerve stimulation),
  • Heart failure,
  • Atrial fibrillation, or acute coronary syndrome in the prior 3 months
  • Dementia (based on the medical record)
  • Previous stroke
  • Non-English-speaking subjects
  • Pregnant and lactating women
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • OSA treated

    Patients with OSA treated with CPAP for at least six months

    Diagnostic Test: Ambulatory blood pressure monitoring and Montreal Cognitive Assessment

  • OSA untreated

    Patients with OSA not treated with CPAP

    Diagnostic Test: Ambulatory blood pressure monitoring and Montreal Cognitive Assessment

  • non-OSA

    Patients underwent a sleep study and were diagnosed not to have OSA

    Diagnostic Test: Ambulatory blood pressure monitoring and Montreal Cognitive Assessment

Interventions

  • Diagnostic testAmbulatory blood pressure monitoring and Montreal Cognitive Assessment

    Noninvasive tests to assess blood pressure control and cognition

06

What researchers measure

Primary outcomes

  1. 24-hour mean systolic blood pressure

    A 24-hour ambulatory blood pressure monitoring will be performed

    Time frame: Within 4 weeks after consent (one time)

  2. Montreal Cognitive Assessment (MoCA)

    Montreal Cognitive Assessment scale (0-30). Lower the scale means more severe cognitive impairment

    Time frame: Within 4 weeks after consent (one time)

Secondary outcomes

  1. Office systolic blood pressure

    Office blood pressure will be record

    Time frame: Within 4 weeks after consent (one time)

  2. Epworth Sleepiness Scale

    Epworth Sleepiness Scale (4-24). Higher scale means more severe daytime sleepiness

    Time frame: Within 4 weeks after consent (one time)

  3. Nocturnal blood pressure dipping

    Percentage of Participants with \>10% drop in nocturnal systolic blood pressure based on the ambulatory BP monitoring

    Time frame: Within 4 weeks after consent (one time)

  4. 24-hour systolic blood pressure <130 mmHg

    24-hour systolic blood pressure \<130 mmHg based on the ambulatory BP monitoring

    Time frame: Within 4 weeks after consent (one time)

  5. 24-hour systolic blood pressure <120 mmHg

    24-hour systolic blood pressure \<120 mmHg based on the ambulatory BP monitoring

    Time frame: Within 4 weeks after consent (one time)

  6. Montreal Cognitive Assessment (MoCA) <27

    Prevalence of participants with Montreal Cognitive Assessment (MoCA) \<27

    Time frame: Within 4 weeks after consent (one time)

  7. Montreal Cognitive Assessment (MoCA) <20

    Prevalence of participants with Montreal Cognitive Assessment (MoCA) \<20

    Time frame: Within 4 weeks after consent (one time)

  8. MoCA score <27 (for those with >10 years of education) and <26 (for those with ≤10 years of education)

    Prevalence of participants with MoCA score \<27 (for those with \>10 years of education) and \<26 (for those with ≤10 years of education)

    Time frame: Within 4 weeks after consent (one time)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Plan to make individual participant data (IPD) available to other researchers at least 5 years after study completion, subjected to final approval by the PI

Supporting information: Clinical study report

Time frame: At least 5 years after study completion

Access criteria: Plan to make individual participant data (IPD) available to other researchers at least 5 years after study completion, subjected to final approval by the PI

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2024; primary completion for Jun 2025, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 17, 2024
StartEst.
Jul 2024
Primary completionEst.
Jun 2025
CompletionEst.
Sep 2025
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06463002
Collaborators
Alexandra Hospital
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Jul 2024 (estimated)
Primary completion
Jun 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Jun 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion